Monoclonal antibodies against human Mac-1 are provided. These antibodies can bind to different states of Mac-1 so as to alter the biofunctions of Mac-1. These antibodies can modulate Th1/Th2 cytokine secretions by TLR-activated immune cells and can be used for the treatments of diseases related to acute and chronic inflammatory disorders, such as infectious diseases, and cancers.

Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin V antibodies, anti-integrin 1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumors are described.

A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

Provided herein is a method of treating a traumatic brain injury in a subject in need thereof, the method including administering to the subject a therapeutically effective amount of radiation. The methods can improve motor function recovery and reverse motor function deficits after traumatic brain injury and/or ischemic stroke in a subject.

Described herein are humanized antibodies that bind to Leukocyte integrin CD11b/CD18 (CD11b, ?M?2, CR3) with enhanced affinity, and methods of use thereof.

The present invention relates to novel multi-functional polypeptides comprising at least two antigen binding sites specific for the CD11b and CD15 cell surface markers. The present invention further relates to a polypeptide, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, the present invention relates to polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and to host cells transformed therewith and their use in the production of said polypeptides. In addition, the present invention relates to compositions, preferably pharmaceutical and diagnostic compositions, comprising any of the afore-described polypeptides, polynucleotides or vectors as well as to kits comprising said compositions. A further object of the present invention is the use of said compositions for therapeutic, diagnostic and cell separation methods.

The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.

Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin V antibodies, anti-integrin 1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumors are described.

The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-, interferon-, interferon-1, interferon-2 or interferon-3.

The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which

a) binds to Mac-1,
b) specifically inhibits the interaction of CD40L with activated Mac-1 and
c) does not induce integrin outside-in signaling.